Dare Bioscience, Inc. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Dare Bioscience, Inc. (DARE) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $3.10 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-03-26
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $3.10M.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.90M.
- 2017-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $846.00K.
- 2016-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $700.00K.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate |
|---|---|
| 2025-12-31 | $3.10M 10-K · filed 2026-03-26 |
| 2024-12-31 | $2.90M 10-K · filed 2026-03-26 |
| 2017-12-31 | $846.00K 10-K · filed 2018-03-28 |
| 2016-12-31 | $700.00K 10-K/A · filed 2017-06-13 |
| 2015-12-31 | $600.00K 10-K/A · filed 2017-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |